Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus
Launched by INTARCIA THERAPEUTICS · Jul 21, 2009
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males or females age 18-70 years
- • Type 2 diabetes mellitus for ≥ 6 months prior to Screening Visit 1
- • On a stable (\> 3 months prior to Screening Visit 1) treatment regimen of metformin monotherapy;
- • Fasting plasma glucose \< 240 mg/dL at Screening Visit 1
- • HbA1c ≥ 7% and ≤ 10% at Screening Visit 1
- Exclusion Criteria:
- • Prior treatment with exenatide
- • Treatment with any of the following antidiabetic agents within 3 months prior to Screening Visit 1: TZDs, sulfonylureas, DPP IV inhibitors, acarbose, or insulin (injected or inhaled)
- • History of type 1 diabetes and/or history of diabetic ketoacidosis
- • Body mass index ≥ 40 kg/m2;
- • History of organ transplantation
About Intarcia Therapeutics
Intarcia Therapeutics is a biopharmaceutical company dedicated to transforming the treatment landscape for chronic diseases through innovative drug delivery systems. With a focus on developing therapies that improve patient adherence and outcomes, Intarcia leverages its proprietary osmotic mini-pump technology to enable continuous, subcutaneous delivery of medications. The company's lead product candidates are aimed at addressing significant unmet needs in diabetes and obesity management. Committed to advancing science and improving quality of life, Intarcia Therapeutics collaborates with healthcare professionals and researchers to develop effective, patient-centered solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Atlanta, Georgia, United States
Rapid City, South Dakota, United States
Dallas, Texas, United States
Chino, California, United States
La Jolla, California, United States
National City, California, United States
Sacramento, California, United States
San Diego, California, United States
Valley Village, California, United States
Longmont, Colorado, United States
Pueblo, Colorado, United States
Bradenton, Florida, United States
Miami, Florida, United States
Miramar, Florida, United States
Pembroke Pines, Florida, United States
St Petersburg, Florida, United States
Sandy Springs, Georgia, United States
Meridian, Idaho, United States
Chicago, Illinois, United States
Avon, Indiana, United States
Wichita, Kansas, United States
Lexington, Kentucky, United States
New Orleans, Louisiana, United States
Kalamazoo, Michigan, United States
Traverse City, Michigan, United States
Troy, Michigan, United States
Ypsilanti, Michigan, United States
Minneapolis, Minnesota, United States
Las Vegas, Nevada, United States
New Hyde Park, New York, United States
Charlotte, North Carolina, United States
Hickory, North Carolina, United States
Cincinatti, Ohio, United States
Franklin, Ohio, United States
Kettering, Ohio, United States
Norman, Oklahoma, United States
Eugene, Oregon, United States
Austin, Texas, United States
Irving, Texas, United States
San Antonio, Texas, United States
West Jordan, Utah, United States
Norfolk, Virginia, United States
Olympia, Washington, United States
Spokane, Washington, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials